Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer
- Conditions
- Breast CancerBreast Implant; ComplicationsRadiotherapy Side EffectBreast Implant Protrusion
- Interventions
- Device: B-Lite® light weight breast implantDevice: Standard silicone-based breast implant
- Registration Number
- NCT03737500
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Brief Summary
Reconstructive surgery with breast implants after total mastectomy for breast cancer is invariably related to several possible complications, such as atrophy of surrounding tissues, skin thinning, capsular contracture, wound dehiscence and inframammary fold break. Such complications are promoted by elastic properties of tissues and their response to gravity forces exerted on breast implant weight, leading to microischaemic events. A poor cosmetic outcome may result up to breast implant exposure, and its removal may become necessary, thus compromising the quality of breast reconstruction. These complications are further favoured by post-mastectomy radiotherapy (PMRT), since irradiation could enhance microischaemia of peri-prosthetic soft tissues and muscle, with subsequent inadequate healing, fibrosis and thinning. Since PMRT has been associated to improved loco-regional control in node-positive breast cancer patients, its use has increased in recent years. On one hand, PMRT has improved loco-regional control but, on the other hand, it has increased the failure rate of breast reconstruction after total mastectomy. Change of timing in breast reconstruction (immediate vs. two-staged by use of tissue expander) has not decreased the complications rate after PMRT. Currently the failure rate of breast reconstruction after total mastectomy and PMRT ranges from 0% to 40%. The present study will recruit 80 participants affected by breast cancer candidated to total mastectomy with immediate breast reconstruction and subsequent PMRT or total mastectomy with reconstruction by tissue expander, subsequent PMRT and then definitive reconstruction with breast implant. Participants will be randomized in two experimental arms: 40 patients will receive final reconstruction by the use of standard silicone-based breast implant and the other 40 patients will receive B-Lite® light weight breast implant. Participants will be followed up at 1, 6, 12 and 24 months, and all patients will undergo breast MRI at 6 months. The primary goal of the present study is to evaluate the failure rate of breast reconstruction (i.e. the need of re-intervention for breast implant removal). Secondary end-points include the overall complications rate, MRI evaluation of breast implant and surrounding tissues, cosmetic outcomes and quality of life including participants' satisfaction with breast reconstruction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 49
- Breast cancer diagnosis with indication of total mastectomy and breast reconstruction
- Indication of post-mastectomy radiation therapy
- Availability to be followed up for 24 months
- Signature of informed consent
- Patients candidated to breast-conserving surgery
- Contraindicated breast reconstruction (severe comorbidities, unfavourable survival outcome expected, distant metastases)
- Patients affected by other solid malignancies
- Pregnancy
- Participation to other clinical studies in the last three months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description B-Lite® light weight breast implant B-Lite® light weight breast implant Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of B-Lite® light weight breast implant Standard silicone-based breast implant Standard silicone-based breast implant Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of standard silicone-based breast implant (i.e. the breast implant commonly used in our institution)
- Primary Outcome Measures
Name Time Method Failure rate of breast reconstruction 24 months Need of re-intervention for breast implant removal for any cause (such as breast implant exposure)
- Secondary Outcome Measures
Name Time Method Change in Quality of life (QoL) measured with BREAST-Q 6, 12, 24 months QoL evaluation included patient's satisfaction with breast reconstruction, using the BREAST-Q score
Magnetic resonance imaging (MRI) of breast implant and surrounding tissues 6 months MRI evaluation for skin/soft tissues thinning, capsular contracture, implant break, chronic seroma
Change in Quality of life (QoL) measured with BIBCQ 6, 12, 24 months QoL evaluation included patient's satisfaction with breast reconstruction using the Body Image after Breast Cancer Questionnaire (BIBCQ)
Overall complications rate 24 months Occurrence of any complication at any time point, such as: capsular contracture, wound dehiscence, skin/soft tissues necrosis, inframammary fold break, implant exposure treated conservatively, hematoma, peri-prosthetic fluid collection, wound/implant infection
Change in cosmetic outcome 1, 6, 12, 24 months Objective evaluation of cosmetic outcome by jugular-nipple/areola complex (NAC) and NAC-inframammary fold distances to evaluate symmetry, objective evaluation of plastic surgeon with serial photographs
Trial Locations
- Locations (1)
Breast Unit - Istituti Clinici Scientifici Maugeri Spa SB
🇮🇹Pavia, Italy